Stomach Acid, Blood pH, and Liver Metabolism: The Stability and Transformation of Acidic Cannabinoids

Abstract

Acidic cannabinoids (e.g., THCA, CBDA) are the dominant phytoconstituents in Cannabis sativa L. and serve as precursors to neutral forms (THC, CBD) via decarboxylation. This is the third work in an integrated series exploring how dietary cannabis inputs interact with Endocannabinoid System (ECS) pathways. This paper examines the role of physiological environments — stomach acidity, blood pH, and hepatic metabolism — in determining the fate, bioavailability, and independent pharmacological activity of ingested acidic cannabinoids. Integrating organic chemistry and pharmacokinetics, the study finds that gastric decarboxylation of acidic cannabinoids is negligible: the reaction's activation energy barrier is largely insurmountable at physiological temperature, and gastric acidity plays no direct catalytic role in overcoming it. Upon absorption, systemic blood pH (7.35–7.45) further stabilizes acidic cannabinoids, which exist almost entirely (>99%) as non-reactive carboxylate anions. Hepatic first-pass metabolism preserves this pattern: acidic cannabinoids are predominantly conjugated intact via UGT1A9, in contrast to neutral THC, which undergoes CYP-mediated oxidation to its own active and inactive metabolites; CBD's position between these two pathways remains unresolved in the literature. The gut microbiome acts as a secondary modulator via β-glucuronidase-mediated deconjugation, potentially enabling enterohepatic recirculation and extending systemic exposure, though this mechanism remains an inference by analogy for cannabinoids specifically rather than a directly demonstrated finding. Beyond their role as precursors, THCA and CBDA act directly on distinct molecular targets independent of any conversion to their neutral forms: CBDA through selective COX-2 inhibition and 5-HT1A receptor potentiation, and THCA through potent PPARγ agonism and weak partial TRPA1 activation. THCA and CBDA have been quantified in human serum following oral administration of Cannabis sativa preparations, at exposures exceeding those of their neutral counterparts, establishing that the intact acid reaches systemic circulation. What fraction of a dose reaches any given target tissue is not addressed here and remains open. Taken together, these findings indicate that ingested acidic cannabinoids reach systemic circulation largely unconverted. Their therapeutic relevance is therefore shaped primarily by their own direct pharmacological activity and by metabolic and microbial processing, rather than by thermal decarboxylation to THC or CBD — a transformation the body's physiological conditions do not provide. Keywords: Dietary cannabinoids; Clinical endocannabinoid deficiency; Entourage effect; Synergistic cannabinoids; Anti-inflammatory acidic cannabinoids; TRP channels cannabinoids (e.g., TRPA1 THCA); 5-HT1A receptor potentiation CBDA; PPAR-gamma agonism cannabinoids; Phytocannabinoid acids; Bioavailability phytocannabinoids; First-pass metabolism cannabinoids